Delayed
OTC Markets
12:34:12 17/05/2024 am IST
|
5-day change
|
1st Jan Change
|
0.0003
USD
|
0.00%
|
|
0.00%
|
0.00%
|
Fiscal Period: January |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
1.573
|
1.043
|
0.493
|
4.777
|
2.156
|
1.197
|
Enterprise Value (EV)
1 |
1.737
|
1.632
|
0.6282
|
4.993
|
2.397
|
1.251
|
P/E ratio
|
-2.33
x
|
-0.2
x
|
-0.28
x
|
-6.58
x
|
-2.61
x
|
-1.94
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
7,70,84,910
x
|
49,31,19,542
x
|
2,34,34,575
x
|
1,76,00,844
x
|
EV / Revenue
|
-
|
-
|
9,82,26,427
x
|
51,54,59,069
x
|
2,60,53,405
x
|
1,84,02,377
x
|
EV / EBITDA
|
-
|
-
|
-
|
-1,11,45,677
x
|
-47,39,605
x
|
-57,19,677
x
|
EV / FCF
|
-
|
32,81,802
x
|
1,00,92,189
x
|
-1,18,29,772
x
|
-1,20,41,056
x
|
-38,76,597
x
|
FCF Yield
|
-
|
0%
|
0%
|
-0%
|
-0%
|
-0%
|
Price to Book
|
-2.06
x
|
-1
x
|
-0.58
x
|
-3.92
x
|
-1.69
x
|
-1.66
x
|
Nbr of stocks (in thousands)
|
6,839
|
32,182
|
6,16,198
|
14,92,765
|
17,82,074
|
23,93,575
|
Reference price
2 |
0.2300
|
0.0324
|
0.000800
|
0.003200
|
0.001210
|
0.000500
|
Announcement Date
|
01/05/18
|
01/05/19
|
24/06/20
|
17/05/21
|
10/05/22
|
09/06/23
|
Fiscal Period: January |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
-
|
0.006395
|
0.009687
|
0.092
|
0.068
|
EBITDA
|
-
|
-
|
-
|
-0.448
|
-0.5058
|
-0.2188
|
EBIT
1 |
-0.1637
|
-1.709
|
-0.3942
|
-0.4787
|
-0.5836
|
-0.2977
|
Operating Margin
|
-
|
-
|
-6,164.89%
|
-4,941.31%
|
-634.23%
|
-437.78%
|
Earnings before Tax (EBT)
1 |
-0.519
|
-2.429
|
-0.6956
|
-0.5389
|
-0.6329
|
-0.5579
|
Net income
1 |
-0.519
|
-2.429
|
-0.6956
|
-0.5389
|
-0.6329
|
-0.5614
|
Net margin
|
-
|
-
|
-10,877.58%
|
-5,563.04%
|
-687.86%
|
-825.66%
|
EPS
2 |
-0.0986
|
-0.1630
|
-0.002879
|
-0.000486
|
-0.000463
|
-0.000258
|
Free Cash Flow
|
-
|
0.4973
|
0.0622
|
-0.4221
|
-0.1991
|
-0.3228
|
FCF margin
|
-
|
-
|
973.29%
|
-4,357.3%
|
-216.37%
|
-474.7%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
01/05/18
|
01/05/19
|
24/06/20
|
17/05/21
|
10/05/22
|
09/06/23
|
Fiscal Period: January |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
0.16
|
0.59
|
0.14
|
0.22
|
0.24
|
0.05
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-0.483
x
|
-0.4764
x
|
-0.2491
x
|
Free Cash Flow
|
-
|
0.5
|
0.06
|
-0.42
|
-0.2
|
-0.32
|
ROE (net income / shareholders' equity)
|
72.1%
|
260%
|
71.2%
|
64.9%
|
69%
|
63.7%
|
ROA (Net income/ Total Assets)
|
-
|
-1,215%
|
-142%
|
-160%
|
-227%
|
-181%
|
Assets
1 |
-
|
0.2
|
0.4883
|
0.336
|
0.2791
|
0.311
|
Book Value Per Share
2 |
-0.1100
|
-0.0300
|
-0
|
-0
|
-0
|
-0
|
Cash Flow per Share
|
-
|
-
|
0
|
0
|
-
|
-
|
Capex
|
-
|
-
|
-
|
0.2
|
0.04
|
-
|
Capex / Sales
|
-
|
-
|
-
|
2,028.39%
|
43.72%
|
-
|
Announcement Date
|
01/05/18
|
01/05/19
|
24/06/20
|
17/05/21
|
10/05/22
|
09/06/23
|
|
1st Jan change
|
Capi.
|
---|
| 0.00% | 875K | | +32.98% | 709B | | +30.77% | 595B | | -1.81% | 367B | | +20.24% | 334B | | +5.99% | 289B | | +14.77% | 239B | | +9.13% | 211B | | -3.97% | 203B | | +9.15% | 171B |
Other Pharmaceuticals
|